| Literature DB >> 34795019 |
Alexandra Taylor1, Sudha S Sundar2, Rebecca Bowen3, Rick Clayton4, Sarah Coleridge5, Christina Fotopoulou6, Sadaf Ghaem-Maghami6, Jonathan Ledermann7, Ranjit Manchanda8, Hilary Maxwell9, Agnieszka Michael10, Tracie Miles11, Shibani Nicum12, Andrew Nordin13, Bruce Ramsay14, Stuart Rundle15, Sarah Williams2, Nicholas J Wood16, Dennis Yiannakis16, Jo Morrison17.
Abstract
During the COVID-19 pandemic, pressures on clinical services required adaptation to how care was prioritised and delivered for women with gynecological cancer. This document discusses potential 'salvage' measures when treatment has deviated from the usual standard of care. The British Gynaecological Cancer Society convened a multidisciplinary working group to develop recommendations for the onward management and follow-up of women with gynecological cancer who have been impacted by a change in treatment during the pandemic. These recommendations are presented for each tumor type and for healthcare systems, and the impact on gynecological services are discussed. It will be important that patient concerns about the impact of COVID-19 on their cancer pathway are acknowledged and addressed for their ongoing care. © IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ.Entities:
Keywords: COVID-19
Mesh:
Year: 2021 PMID: 34795019 DOI: 10.1136/ijgc-2021-002942
Source DB: PubMed Journal: Int J Gynecol Cancer ISSN: 1048-891X Impact factor: 3.437